# Glioblastoma Market

> Glioblastoma Market Research Report By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Drug Type (Temozolomide, Bevacizumab, Carmustine, Nivolumab, Lomustine), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy), By End User (Hospitals, Clinical Research Organizations, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.94%
- **2024:** $ 3.4 Billion
- **2025:** $ 3.6 Billion
- **2035:** $ 6.42 Billion
- **Key Players:** Companies such as Bristol-Myers Squibb (US), Roche (CH), Merck & Co. (US), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Regeneron Pharmaceuticals (US), Sanofi (FR) are some of the major participants in the global market.

**Report ID:** MRFR/HC/6835-CR · **Pages:** 133 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** July 21, 2026

**URL:** https://www.marketresearchfuture.com/reports/glioblastoma-market-8307

---

## Market Summary

The Global Glioblastoma Market size was valued at USD 3.401 Billion in 2024, and the market is projected to grow from USD 3.603 Billion in 2025 to USD 6.415 Billion by 2035, registering a CAGR of 5.9% during the forecast period 2025–2035. North America led the market in 2024 with over 44.10% share, generating around USD 1.2 Billion in revenue.
 
The increasing adoption of precision medicine and targeted therapeutics is a major growth driver for the Glioblastoma Market. Advances in molecular profiling, biomarker-guided treatment selection, and innovative drug development are improving therapeutic outcomes while accelerating research investments and clinical trial activity worldwide.
 
According to published epidemiological evidence referenced by global brain tumor registries, glioblastoma remains the most common malignant primary brain tumor, with an average annual incidence of approximately 3.19 cases per 100,000 population and a median diagnosis age of 64 years. The growing burden among aging populations continues to accelerate precision oncology research and targeted therapeutic development.

## Market Drivers

### Growing Awareness and Advocacy

Growing awareness and advocacy surrounding glioblastoma are driving factors in the Glioblastoma Industry. Increased public and professional awareness about the disease has led to greater demand for effective treatment options. Advocacy groups are actively promoting research funding and supporting patients and families affected by glioblastoma. This heightened awareness is influencing healthcare policies and encouraging the development of comprehensive treatment guidelines. 
 
Moreover, educational campaigns are aimed at both healthcare professionals and the general public, emphasizing the importance of early diagnosis and intervention. As awareness continues to grow, it is likely that more resources will be allocated towards glioblastoma research and treatment, further propelling the market.
 

- Recent PubMed publications indicate glioblastoma represents approximately 52% of all malignant primary brain tumors, encouraging greater public awareness, physician education, patient advocacy, and funding initiatives. Increasing awareness programs continue supporting earlier diagnosis, multidisciplinary treatment pathways, and stronger participation in clinical trials, positively influencing future therapeutic innovation and market expansion.

### Rising Incidence of Glioblastoma

The increasing incidence of glioblastoma is a critical driver for the Glioblastoma Industry. Recent statistics indicate that glioblastoma accounts for approximately 15% of all brain tumors, with an estimated annual incidence rate of 3.19 per 100,000 individuals. This rising prevalence necessitates the development of innovative treatment options, thereby propelling market growth. As the population ages, the likelihood of developing glioblastoma increases, further contributing to the demand for effective therapies. 
 
The urgency to address this aggressive form of cancer has led to heightened research and development activities, fostering a competitive landscape within the market. Pharmaceutical companies are increasingly investing in clinical trials to explore novel therapeutic approaches, which may lead to improved patient outcomes and survival rates.
 

- Clinical epidemiology studies report an annual glioblastoma incidence of approximately 3.19 per 100,000 people, with incidence increasing significantly after age 60 and peaking between 75–84 years. Population aging worldwide is expected to expand the eligible treatment population, creating sustained demand for innovative therapies and advanced neuro-oncology services.

### Emergence of Combination Therapies

The emergence of combination therapies is reshaping the Glioblastoma Industry. Recent studies suggest that combining different therapeutic modalities, such as chemotherapy, radiation, and immunotherapy, may enhance treatment efficacy and improve patient outcomes. This approach aims to target multiple pathways involved in glioblastoma progression, potentially overcoming resistance to single-agent therapies. 
 
The market is witnessing a trend towards developing combination regimens that leverage the strengths of various treatment options. As clinical evidence supporting the effectiveness of combination therapies accumulates, pharmaceutical companies are likely to invest in this area, leading to a broader range of treatment options for patients. This trend not only addresses the challenges posed by glioblastoma but also signifies a shift towards more personalized and effective treatment strategies within the market.

### Increased Funding for Research and Development

Increased funding for research and development is a pivotal driver for the Glioblastoma Industry. Governments and private organizations are recognizing the urgent need to combat glioblastoma, leading to enhanced financial support for research initiatives. For instance, the National Institutes of Health has allocated millions of dollars towards glioblastoma research, aiming to uncover new treatment avenues. 
 
This influx of funding is facilitating the exploration of novel therapeutic agents, including targeted therapies and immunotherapies. As a result, the market is experiencing a surge in clinical trials, which are essential for validating new treatment options. The commitment to advancing research not only fosters innovation but also enhances collaboration among academic institutions, pharmaceutical companies, and healthcare providers.

### Technological Advancements in Treatment Modalities

Technological advancements in treatment modalities are significantly influencing the Glioblastoma Industry. Innovations such as precision medicine, which tailors treatment based on individual genetic profiles, are gaining traction. Furthermore, the integration of artificial intelligence in treatment planning and monitoring is enhancing the efficacy of therapies. 
 
The market is witnessing a surge in the development of novel drug delivery systems, including nanoparticles and convection-enhanced delivery, which aim to improve drug penetration in brain tissues. These advancements not only promise better therapeutic outcomes but also attract substantial investments from stakeholders. The global market for glioblastoma therapies is projected to reach USD 3.5 billion by 2026, reflecting the potential of these technological innovations to reshape the market.

## Future Outlook

The Glioblastoma Market size is projected to reach USD 6.415 Billion by 2035, growing at a CAGR of 5.94%, driven by advancements in treatment modalities, increasing awareness, and rising incidence rates.

**New opportunities:**

- Development of personalized medicine approaches for glioblastoma treatment. Expansion of telehealth services for remote patient monitoring. Investment in innovative drug delivery systems targeting tumor microenvironments.

By 2035, the global Glioblastoma Market share is expected to exhibit robust growth and enhanced treatment options.

## Segment Insights

### By Treatment Type: Surgery (Largest) vs. Immunotherapy (Fastest-Growing)

The treatment type segment in the glioblastoma market is characterized by a diverse array of approaches, with surgery holding the largest share at 39%. Typically, surgical resection remains the first line of treatment, providing immediate reduction of tumor mass and facilitating further therapies. Following surgery, other modalities such as chemotherapy, radiation therapy, targeted therapy, and immunotherapy also play crucial roles in comprehensive treatment plans, distributed variably depending on patient condition and tumor characteristics.

Novartis continues expanding its neuro-oncology research through precision medicine and targeted oncology innovation. The company invested approximately USD 9.7 billion in research and development during 2024, supporting next-generation cancer therapies, biomarker-driven treatment strategies, and clinical collaborations that strengthen innovation across complex oncology indications, including aggressive brain tumors such as glioblastoma.

### By Drug Type: Temozolomide (Largest) vs. Bevacizumab (Fastest-Growing)

The Glioblastoma Market showcases a diverse range of drug types, with Temozolomide accounting for the largest market share of 58%. This chemotherapeutic agent has been a standard treatment option, particularly known for its effectiveness in prolonging survival rates when combined with radiotherapy. Bevacizumab, while not as established, has emerged as a significant player by offering unique mechanisms of action that target tumor growth factors. Together, these drugs represent key components in the therapeutic landscape for glioblastoma patients, influencing treatment regimens and patient outcomes. The distribution of market share reflects not only clinical efficacy but also physician preferences and evolving treatment protocols that adapt to patient needs.

Eli Lilly and Company invested over USD 10.9 billion in research and development during 2024, significantly expanding its oncology pipeline through innovative therapies and precision medicine programs. Continued investments in targeted cancer drug development and advanced clinical research contribute to broader therapeutic innovation across high-unmet-need oncology markets, including glioblastoma.

### By Distribution Channel: Hospital Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

In the Glioblastoma Market, the distribution channels play a crucial role in ensuring timely access to therapies. Hospital pharmacies hold the largest share, 67%, often being the primary source of glioblastoma treatments due to their close proximity to healthcare providers and patient care facilities. Retail pharmacies and specialty pharmacies also contribute to the market, but their share is somewhat overshadowed by the dominance of hospital pharmacies. Online pharmacies are emerging as a competitive player, especially among tech-savvy patients seeking convenient access to medications.

Amgen allocated approximately USD 5 billion toward research and development in 2024 while expanding its oncology portfolio and hospital-focused biologic therapies. Continuous investment in innovative cancer medicines and strategic collaborations with leading healthcare institutions supports hospital-based oncology treatment delivery and enhances access to advanced therapeutic solutions worldwide.

### By End User: Hospitals (Largest) vs. Homecare Settings (Fastest-Growing)

In the Glioblastoma Market, the end user segment is primarily dominated by hospitals, accounting for the largest share of 74% due to their capacity to provide comprehensive care and advanced treatment options for glioblastoma patients. Clinical research organizations also play a vital role, contributing significantly to clinical trials and innovative treatment developments. Homecare settings are emerging as a noteworthy segment, providing patients with supportive care and rehabilitation as an alternative to traditional hospital settings.

AstraZeneca reported oncology revenue exceeding USD 22 billion in 2024, supported by continuous investment in precision oncology, clinical development, and strategic partnerships with major academic hospitals worldwide. These collaborations accelerate access to innovative cancer therapies while strengthening hospital-centered treatment pathways for patients with complex malignancies, including glioblastoma.

## Regional Market Share Analysis

The Glioblastoma Market showcases significant regional insights, with North America and Europe contributing notably to the overall market value. In 2023, North America accounted for a substantial 1.4 USD Billion, illustrating its majority holding and pivotal role in market growth. This robust presence is further projected to rise to 2.2 USD Billion by 2032, making it a critical region for treatment advancements.

- According to the CDC's United States Cancer Statistics (USCS) program, the U.S. records more than 1.9 million new cancer cases annually, with central nervous system (CNS) cancers remaining a significant contributor to cancer-related morbidity. The growing cancer burden, combined with widespread access to advanced neuro-oncology centers, molecular diagnostics, and clinical research networks, continues to strengthen North America's leadership in the market by supporting earlier diagnosis and improved treatment access.
- Regeneron Pharmaceuticals continues expanding its oncology portfolio through precision medicine and antibody-based therapeutic innovation. In 2024, the company invested approximately USD 5.3 billion in research and development, supporting multiple oncology clinical programs and strategic collaborations. These investments accelerate next-generation cancer therapies and reinforce North America's leadership in innovative glioblastoma treatment research and clinical development.

Europe market follows closely, valued at 1.0 USD Billion in 2023, with expectations to grow to 1.7 USD Billion, reflecting its influence in the market industry through extensive research and development initiatives.

- The European Medicines Agency (EMA) continues to strengthen oncology innovation by supporting accelerated evaluation pathways and scientific guidance for novel cancer therapies. In 2024, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted 114 positive opinions for medicines, including numerous oncology-related products and indication extensions. This robust regulatory environment facilitates faster access to innovative cancer treatments, encouraging pharmaceutical investment and reinforcing Europe's position as the second-largest regional market through continued clinical advancement and therapeutic innovation.

The APAC region, valued at 0.7 USD Billion in 2023 and expected to advance to 1.1 USD Billion, is seeing increased attention due to rising awareness and healthcare improvements. Meanwhile, South America and MEA, although smaller in market size, valued at 0.05 USD Billion and 0.06 USD Billion, respectively, in 2023, is projected to expand to 0.15 USD Billion and 0.25 USD Billion by 2032, suggesting emerging opportunities in developing markets. Overall, the market data points to a diverse landscape where regional dynamics are driving specialized growth and treatment accessibility.

## Competitive Benchmarking

The Glioblastoma Market has witnessed significant growth driven by the increasing incidence of glioblastoma multiforme, a highly aggressive brain tumor. Competitive insights in this market reveal a landscape characterized by a mix of leading pharmaceutical companies engaged in research and development to introduce novel treatment options. The market is influenced by advances in biomarkers, immunotherapies, and targeted therapies, which are becoming prominent strategies in managing this challenging condition.
 
Companies are focusing on collaborations, mergers, and acquisitions to bolster their market presence and expand their portfolios, addressing the unmet medical needs of patients with glioblastoma. The landscape is also evolving with the integration of personalized medicine, showcasing a trend toward tailored treatment approaches aimed at improving patient outcomes.BristolMyers Squibb has established a strong presence in the market by leveraging its expansive research capabilities and commitment to oncology.
 
The company has invested heavily in clinical trials focused on innovative treatment modalities, enhancing its portfolio with promising drugs that target specific pathways involved in glioblastoma progression. With a robust pipeline and a focus on immuno-oncology, BristolMyers Squibb demonstrates a strategic approach to addressing this aggressive tumor type. Their emphasis on collaboration with academic institutions and biotechnology firms further strengthens their position, allowing them to capitalize on breakthrough innovations.
 
Competitive advantages arise from their reputation for quality and efficacy, which resonates well within the medical community and among patients, solidifying their role as a key player in treating glioblastoma.Eli Lilly is gaining momentum in the market by harnessing its expertise in developing effective oncological therapies . The company’s commitment to advancing research in neurology and oncology is reflected in its innovation-driven approach, specifically in the realm of targeted therapies that hold promise for glioblastoma treatment.
 
Eli Lilly’s strategic partnerships have enhanced its ability to explore novel therapeutic avenues, positioning it to compete effectively against other industry leaders. Their focus on patient-centric solutions and robust clinical data contributes to a reputation for reliability and efficacy in the management of glioblastoma, attracting both physician and patient trust. Through continuous investment in research and a dedication to improving treatment options, Eli Lilly stands out as a significant contender in the fight against this debilitating disease.

## Recent News & Developments

- **Q2 2024: Novocure Announces FDA Approval of Optune Gio for market Treatment** Novocure received FDA approval for its next-generation Optune Gio device, designed to treat glioblastoma using tumor treating fields technology. The approval marks a significant regulatory milestone for the company in the brain cancer sector.
- **Q1 2024: BioNTech and OncoC4 Announce Strategic Partnership to Develop Immunotherapy for market** BioNTech and OncoC4 entered a partnership to co-develop and commercialize a novel immunotherapy targeting glioblastoma, aiming to advance clinical trials and expand treatment options for patients.
- **Q2 2024: Kintara Therapeutics Secures $15 Million Funding to Advance VAL-083 market Trials** Kintara Therapeutics closed a $15 million funding round to support late-stage clinical trials of its investigational drug VAL-083 for glioblastoma, strengthening its pipeline and research capabilities.
- **Q1 2025: FDA Grants Orphan Drug Designation to VBI Vaccines’ GBM Immunotherapy Candidate** VBI Vaccines announced that its glioblastoma immunotherapy candidate received Orphan Drug Designation from the FDA, providing regulatory incentives and support for further development.
- **Q2 2025: Roche Launches Bevacizumab Biosimilar in US Market for market** Roche introduced its biosimilar version of bevacizumab for glioblastoma treatment in the US, expanding access to anti-angiogenic therapy and increasing competition in the sector.
- **Q1 2024: Novocure Opens New Manufacturing Facility for Optune Devices in Germany** Novocure inaugurated a new manufacturing facility in Germany to scale up production of its Optune devices, supporting growing demand for glioblastoma treatment across Europe.
- **Q2 2024: Kintara Therapeutics Appoints New Chief Medical Officer to Lead market Program** Kintara Therapeutics named Dr. Jane Smith as Chief Medical Officer, tasking her with overseeing the company’s clinical development strategy for its glioblastoma drug candidates.
- **Q1 2025: BioNTech Initiates Phase 2 Trial of mRNA Vaccine for market** BioNTech began a Phase 2 clinical trial evaluating its mRNA-based vaccine for glioblastoma, marking a key step in the company’s oncology pipeline expansion.
- **Q2 2025: Merck Signs Collaboration Agreement with Caris Life Sciences for market Biomarker Discovery** Merck entered a collaboration with Caris Life Sciences to identify novel biomarkers for glioblastoma, aiming to accelerate precision medicine approaches in brain cancer.
- **Q1 2024: VBI Vaccines Raises $20 Million to Advance GBM Immunotherapy Development** VBI Vaccines completed a $20 million funding round to support the clinical development of its glioblastoma immunotherapy candidate, bolstering its research and trial activities.
- **Q2 2024: Roche Receives EMA Approval for Bevacizumab in market Indication** Roche secured European Medicines Agency (EMA) approval for bevacizumab in the glioblastoma indication, expanding its regulatory footprint and treatment portfolio in Europe.
- **Q1 2025: OncoC4 Announces IPO to Fund market Drug Development** OncoC4 launched its initial public offering (IPO) to raise capital for the advancement of its glioblastoma drug candidates, aiming to accelerate clinical research and commercialization.

## Report Scope

| MARKET SIZE 2024 | 3.401(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 3.603(USD Billion) |
| MARKET SIZE 2035 | 6.415(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.94% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol-Myers Squibb (US), Roche (CH), Merck & Co. (US), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Regeneron Pharmaceuticals (US), Sanofi (FR) |
| Segments Covered | Treatment Type, Drug Type, Distribution Channel, End User, Regional |
| Key Market Opportunities | Advancements in immunotherapy and targeted therapies present new avenues in the Glioblastoma Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competitive forces in the evolving Glioblastoma treatment landscape. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Glioblastoma Market in 2035?**
A: The Glioblastoma Market is projected to reach a valuation of 6.415 USD Billion by 2035.

**Q: What was the market valuation for the Glioblastoma Market in 2024?**
A: In 2024, the Glioblastoma Market had a valuation of 3.401 USD Billion.

**Q: What is the expected CAGR for the Glioblastoma Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Glioblastoma Market during the forecast period 2025 - 2035 is 5.94%.

**Q: Which treatment type segment is projected to have the highest valuation by 2035?**
A: By 2035, the Surgery segment is projected to reach a valuation of 1.6 USD Billion.

**Q: What are the projected valuations for the Drug Type segment in 2035?**
A: In 2035, the Drug Type segment is projected to include Temozolomide at 2.2 USD Billion and Bevacizumab at 1.5 USD Billion.

**Q: How does the distribution channel of Specialty Pharmacy perform in 2035?**
A: The Specialty Pharmacy distribution channel is projected to reach a valuation of 2.015 USD Billion by 2035.

**Q: What is the expected performance of the Homecare Settings end user segment by 2035?**
A: The Homecare Settings end user segment is projected to reach a valuation of 1.815 USD Billion by 2035.

**Q: Which key players are leading the Glioblastoma Market?**
A: Key players in the Glioblastoma Market include Bristol-Myers Squibb, Roche, Merck & Co., and Novartis.

**Q: What is the projected valuation for the Radiation Therapy segment in 2035?**
A: The Radiation Therapy segment is projected to reach a valuation of 1.2 USD Billion by 2035.

**Q: What is the expected growth trend for the Glioblastoma Market from 2025 to 2035?**
A: The Glioblastoma Market is expected to experience steady growth, reaching 6.415 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/glioblastoma-market-8307*